Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Loading news article.

NovaBridge Biosciences and ABL Bio to Present Clinical Data at ESMO 2026 | WAPE

Back All news

Newsfiscal.ai

NovaBridge Biosciences and ABL Bio to Present Clinical Data at ESMO 2026

Oct 19, 2026, 09:03 ET · Published

View source

Article summary

NovaBridge Biosciences and its partner ABL Bio will present updated clinical study results for their 4-1BB-based bispecific antibody candidates, Givastomig and Ragistomig, at the European Society for Medical Oncology (ESMO) 2026 annual meeting.

An excerpt from the original article.

Related companies

NovaBridge Biosciences American Depositary SharesNBPView stock

NovaBridge Biosciences and ABL Bio to Present Clinical Data at ESMO 2026

Article summary

Related companies

Analyzed by WAPE AI.

Comments —